18 
to this bill will have an impact on the amount of additional paper- 
work the additional burden cannot be estimated. 
VIII. Section-by- Section” Analysis — S. 1217 
Section 1. Short title, names the act (S. 1217) the “Recombinant 
DXA Safety Regulation Act.” 
Section 2, Findings, provides that the Congress finds that — 
(1) work with recombinant DXA. will improve the understand- 
ing of basic biological processes ; 
(2) recombinant DXA activities not only offer many potential 
benefits, but also raise serious questions regarding potential 
hazards : 
(3) microorganisms containing recombinant DXA could spread 
throughout the United States and to other countries, adversely 
affecting human health, the environment, industry, and agricul- 
ture; 
(4) that the public health must be protected by requiring that 
all recombinant DXA activities comply with standards of safety 
and performance and that there must be a uniform Federal policy 
regarding such standards ; and therefore 
(5) it is necessary to establish a Commission, known as the 
Xational Recombinant DXA Safety Regulation Commission, to 
assure that recombinant DXA activities be conducted in a manner 
to protect the public health and welfare of the American people ; 
and 
(6) all recombinant DXA activities are either in interstate 
commerce or substantially affect such commerce so that regula- 
tions and licensure by the Xational Recombinant DNA Safety 
Commission are necessary to effectively regulate such commerce. 
Section 3 amends the Public Health Service Act by adding after 
title XVII the following new title : 
Title XVIII — Xational Recombinant DXA Safety Regulation 
Commission 
ESTABLISHMENT OF COMMISSION 
Section 1801 establishes within the Department of Health, Educa- 
tion, and Welfare the Xational Recombinant DXA Safety Regulation 
Commission. The Commission shall be composed of 11 members ap- 
pointed by the President within 60 days from the date of enactment 
of the Act. The President shall appoint six members of the Commis- 
sion from individuals — (a) who are not and have never been profes- 
sionally engaged in biological research, (b) who are members of the 
general public including persons who are trained or have experience 
in the fields of medicine, law, ethics, education, physical, behavioral, 
and social sciences, philosophy, humanities, health administration, 
government, or public affairs, and (c) who have no financial interest 
in recombinant DXA activities. The President shall appoint five mem- 
bers of the Commission from individuals who are or have been pro- 
fessionally engaged in biological research, (b) who are qualified to 
serve on the Commission by virtue of their training, experience or 
background, and (c) who have no financial interest in recombinant 
[ 758 ] 
